May 19, 2023 06:53 AM EDTUpdated 07:10 AM
Peer Review

Vir en­lists J&J vet to run busi­ness de­vel­op­ment; Gilead finds Kite suc­ces­sor to Christi Shaw

Kathy Wong

Editor

→ Af­ter grab­bing $10 mil­lion in fund­ing from the Bill & Melin­da Gates Foun­da­tion for its HIV vac­cine ear­ly this month, Vir Biotech­nol­o­gy …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Pfiz­er CEO says op­por­tu­ni­ties with Trump ‘clear­ly out­weigh’ the risks for phar­ma

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times